IL245588B - Compositions of triheptanoin oil and their use - Google Patents

Compositions of triheptanoin oil and their use

Info

Publication number
IL245588B
IL245588B IL245588A IL24558816A IL245588B IL 245588 B IL245588 B IL 245588B IL 245588 A IL245588 A IL 245588A IL 24558816 A IL24558816 A IL 24558816A IL 245588 B IL245588 B IL 245588B
Authority
IL
Israel
Prior art keywords
compositions
triheptanoin oil
triheptanoin
oil
Prior art date
Application number
IL245588A
Other languages
English (en)
Hebrew (he)
Other versions
IL245588A0 (en
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of IL245588A0 publication Critical patent/IL245588A0/en
Publication of IL245588B publication Critical patent/IL245588B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL245588A 2013-11-14 2016-05-10 Compositions of triheptanoin oil and their use IL245588B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14
PCT/US2014/065693 WO2015073816A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Publications (2)

Publication Number Publication Date
IL245588A0 IL245588A0 (en) 2016-06-30
IL245588B true IL245588B (en) 2021-08-31

Family

ID=53058066

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245588A IL245588B (en) 2013-11-14 2016-05-10 Compositions of triheptanoin oil and their use

Country Status (18)

Country Link
US (6) US20160243071A1 (enExample)
EP (2) EP3068383B1 (enExample)
JP (4) JP2017501972A (enExample)
KR (1) KR102291310B1 (enExample)
CN (2) CN113181158A (enExample)
AR (2) AR099353A1 (enExample)
AU (1) AU2014348470B2 (enExample)
CA (2) CA3197154A1 (enExample)
CL (1) CL2016001130A1 (enExample)
ES (1) ES2833294T3 (enExample)
IL (1) IL245588B (enExample)
MX (2) MX383005B (enExample)
MY (1) MY177028A (enExample)
PE (1) PE20161024A1 (enExample)
PH (1) PH12016500821A1 (enExample)
RU (1) RU2016123169A (enExample)
TW (1) TWI640327B (enExample)
WO (1) WO2015073816A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383005B (es) * 2013-11-14 2025-03-13 Ultragenyx Pharmaceutical Inc Composiciones solidas de trigliceridos y usos de estas.
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US12419852B2 (en) 2018-08-27 2025-09-23 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
CA2212047C (en) * 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
NZ513329A (en) * 1999-02-05 2003-11-28 Baylor University Medical Ct Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US8399515B2 (en) * 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
CA2573054C (en) 2004-07-02 2012-10-09 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
CA2599667C (en) * 2005-03-10 2014-12-16 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxy carboxylic acids
CN101137359B (zh) * 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
US8642012B2 (en) 2008-04-29 2014-02-04 Hyperion Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
WO2011159634A1 (en) * 2010-06-14 2011-12-22 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
CN101919453B (zh) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
BR112014007357B1 (pt) 2011-09-30 2022-12-06 Immedica Pharma Ab Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
WO2013158616A1 (en) 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency
CN104955450A (zh) 2012-12-13 2015-09-30 达拉斯贝勒研究院 用于治疗葡萄糖转运体1缺乏症的三庚酸甘油酯
MX383005B (es) * 2013-11-14 2025-03-13 Ultragenyx Pharmaceutical Inc Composiciones solidas de trigliceridos y usos de estas.

Also Published As

Publication number Publication date
CN113181158A (zh) 2021-07-30
TW201609189A (zh) 2016-03-16
US20160243071A1 (en) 2016-08-25
AR130666A2 (es) 2025-01-08
CA2929688A1 (en) 2015-05-21
CA3197154A1 (en) 2015-05-21
CN105764497A (zh) 2016-07-13
EP3068383A1 (en) 2016-09-21
EP3068383A4 (en) 2017-11-08
WO2015073816A1 (en) 2015-05-21
CA2929688C (en) 2023-06-13
JP2022107017A (ja) 2022-07-20
RU2016123169A (ru) 2017-12-19
MX2021001790A (es) 2021-04-19
US20250120936A1 (en) 2025-04-17
ES2833294T3 (es) 2021-06-14
AU2014348470B2 (en) 2020-01-30
EP3782610A1 (en) 2021-02-24
MX2016006329A (es) 2016-09-06
TWI640327B (zh) 2018-11-11
US20250120934A1 (en) 2025-04-17
KR20160084407A (ko) 2016-07-13
PH12016500821A1 (en) 2016-06-13
US20200069631A1 (en) 2020-03-05
AR099353A1 (es) 2016-07-20
PE20161024A1 (es) 2016-11-10
EP3068383B1 (en) 2020-09-16
IL245588A0 (en) 2016-06-30
US20230181513A1 (en) 2023-06-15
US20250120935A1 (en) 2025-04-17
JP2017501972A (ja) 2017-01-19
CL2016001130A1 (es) 2017-01-20
JP2020111585A (ja) 2020-07-27
MX383005B (es) 2025-03-13
AU2014348470A1 (en) 2016-05-26
MY177028A (en) 2020-09-02
KR102291310B1 (ko) 2021-08-23
JP2024129109A (ja) 2024-09-26

Similar Documents

Publication Publication Date Title
IL285780A (en) Preparations of tmprss6 irna and methods of using them
IL244850A0 (en) Stabilized epinaconazole preparations, and their uses
SG11201507867RA (en) Antimicrobial compositions and methods of use
EP2996672A4 (en) COSMETIC COMPOSITIONS WITH MICROALGEN OIL
IL265876A (en) Preparations that include 15-ohepa and methods of using them
IL246985B (en) stable liquid preparations
SG10201708595YA (en) Cenicriviroc compositions and methods of making and using the same
SG11201507158WA (en) Stabilized polymer compositions and methods of making same
GB201321693D0 (en) Composition and uses thereof
PL3205683T3 (pl) Kompozycje i urządzenia z poli-4-hydroksymaślanu
PL2997118T3 (pl) Zastosowanie politetrahydrofuranów w kompozycjach olejów smarujących
SG11201506869YA (en) Antimicrobial compositions and related methods of use
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
GB201305813D0 (en) Compositions and methods
EP3007720A4 (en) COMPOSITION COMPRISING THE GC MACROPHAGE ACTIVATION FACTOR AND USES THEREOF
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
SG11201507389RA (en) Integration of hydro-dechlorination and hydro-regeneration
IL245588B (en) Compositions of triheptanoin oil and their use
ZA201505825B (en) Coating compositions and methods of use
GB201518119D0 (en) Lubricant additives and compositions
IL239899A0 (en) Preparations of thiazomycin compounds
HUE057170T2 (hu) Poliészter-kompozíciók alkalmazása
GB201308242D0 (en) Compositions and uses thereof
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201301022D0 (en) Composition and uses thereof